HomeCompareCBBHF vs ABBV

CBBHF vs ABBV: Dividend Comparison 2026

CBBHF yields 3992.02% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CBBHF wins by $7038408636820.23M in total portfolio value
10 years
CBBHF
CBBHF
● Live price
3992.02%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7038408636820.33M
Annual income
$6,707,864,260,492,553,000.00
Full CBBHF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CBBHF vs ABBV

📍 CBBHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBBHFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBBHF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBBHF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBBHF
Annual income on $10K today (after 15% tax)
$339,321.36/yr
After 10yr DRIP, annual income (after tax)
$5,701,684,621,418,670,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CBBHF beats the other by $5,701,684,621,418,649,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBBHF + ABBV for your $10,000?

CBBHF: 50%ABBV: 50%
100% ABBV50/50100% CBBHF
Portfolio after 10yr
$3519204318410.22M
Annual income
$3,353,932,130,246,289,000.00/yr
Blended yield
95.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CBBHF
No analyst data
Altman Z
8.8
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBBHF buys
0
ABBV buys
0
No recent congressional trades found for CBBHF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBBHFABBV
Forward yield3992.02%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$7038408636820.33M$102.3K
Annual income after 10y$6,707,864,260,492,553,000.00$24,771.77
Total dividends collected$7015858891478.01M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CBBHF vs ABBV ($10,000, DRIP)

YearCBBHF PortfolioCBBHF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$409,902$399,201.60$11,550$430.00+$398.4KCBBHF
2$15,731,433$15,292,838.50$13,472$627.96+$15.72MCBBHF
3$565,353,313$548,520,679.36$15,906$926.08+$565.34MCBBHF
4$19,027,950,361$18,423,022,315.76$19,071$1,382.55+$19027.93MCBBHF
5$599,854,207,291$579,494,300,405.11$23,302$2,095.81+$599854.18MCBBHF
6$17,715,207,654,637$17,073,363,652,836.21$29,150$3,237.93+$17715207.63MCBBHF
7$490,188,440,412,516$471,233,168,222,053.44$37,536$5,121.41+$490188440.37MCBBHF
8$12,710,718,187,796,452$12,186,216,556,555,060.00$50,079$8,338.38+$12710718187.75MCBBHF
9$308,919,977,876,429,600$295,319,509,415,487,360.00$69,753$14,065.80+$308919977876.36MCBBHF
10$7,038,408,636,820,333,000$6,707,864,260,492,553,000.00$102,337$24,771.77+$7038408636820.23MCBBHF

CBBHF vs ABBV: Complete Analysis 2026

CBBHFStock

Cobalt Blue Holdings Limited engages in the exploration and evaluation of early-stage cobalt resources in Australia. It holds 100% interest in the Broken Hill Cobalt project comprises g five exploration licenses and two mining leases covering an area of approximately 220 square kilometers located in the Broken Hill, New South Wales. The company was incorporated in 2016 and is based in North Sydney, Australia.

Full CBBHF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CBBHF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBBHF vs SCHDCBBHF vs JEPICBBHF vs OCBBHF vs KOCBBHF vs MAINCBBHF vs JNJCBBHF vs MRKCBBHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.